Possible dulaglutide-associated cholecystitis with safe continuation post cholecystectomy

• Main Authors: Bjurstrom, M. (Author), Butler, J. (Author), Marceau, A. (Author)
• Format: Article
• Language: English
• Published: Oxford University Press 2021
• Subjects: acute cholecystitis; Acute cholecystitis; aged; Aged; alpha tocopherol; Article; body weight loss; case report; cholecystectomy; Cholecystectomy; cholecystitis; Cholecystitis; clinical article; collagen; computer assisted tomography; Diabetes Mellitus, Type 2; dulaglutide; Dulaglutide; emergency ward; fusion protein; Gallbladder diseases; gallstone; gangrene; glipizide; glipizide plus metformin; GLP-1 agonists; glucagon like peptide; Glucagon-Like Peptides; hemoglobin A1c; human; Humans; hyperglycemia; immunoglobulin Fc fragment; Immunoglobulin Fc Fragments; insulin glargine; loss of appetite; male; Male; metformin; nausea; non insulin dependent diabetes mellitus; outpatient; pioglitazone; priority journal; Recombinant Fusion Proteins; rosuvastatin; ubiquinone; upper abdominal pain
• Online Access: View Fulltext in Publisher

 Purpose. Possible dulaglutide-induced cholecystitis, with successful resumption of dulaglutide after cholecystectomy, is discussed. Summary. A 72-year-old White man was started on dulaglutide for outpatient management of type 2 diabetes, in addition to his existing antihyperglycemic regimen of metformin, glipizide, pioglitazone, and insulin glargine. His glycated hemoglobin (HbA1c) concentration improved from 8.2% to 7.2% with the addition of dulaglutide. Furthermore, the use of dulaglutide did not lead to weight loss. After 16 months of treatment with dulaglutide, he presented to the emergency room with nausea, loss of appetite, and progressive sharp, nonradiating right upper quadrant pain. Based on symptom presentation, laboratory workup, and computed tomography scan results, acute cholecystitis was diagnosed. He underwent a cholecystectomy to remove what was found to be a gangrenous gallbladder. Per documented surgical dictation from the cholecystectomy, the gallbladder was removed, but portions of the biliary tree were left intact. The patient was continued on dulaglutide postoperatively without recurrence of bile stones, biliary tree disease, or abdominal symptoms at 8 months after initial cholecystitis incident. Conclusion. A male patient with possible dulaglutide-induced cholecystitis was successfully continued on dulaglutide therapy post cholecystectomy without recurrent complications within the biliary tract. © 2021 Oxford University Press. All rights reserved.